[go: up one dir, main page]

DE60332481D1 - Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems - Google Patents

Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems

Info

Publication number
DE60332481D1
DE60332481D1 DE60332481T DE60332481T DE60332481D1 DE 60332481 D1 DE60332481 D1 DE 60332481D1 DE 60332481 T DE60332481 T DE 60332481T DE 60332481 T DE60332481 T DE 60332481T DE 60332481 D1 DE60332481 D1 DE 60332481D1
Authority
DE
Germany
Prior art keywords
treatment
peptides
diseases
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332481T
Other languages
German (de)
English (en)
Inventor
Zhi Cheng Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Novavac Bio-Tec Co Ltd Su Zhou Cn
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60332481D1 publication Critical patent/DE60332481D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60332481T 2002-12-06 2003-12-05 Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems Expired - Lifetime DE60332481D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43162002P 2002-12-06 2002-12-06
PCT/GB2003/005323 WO2004052922A2 (fr) 2002-12-06 2003-12-05 Lesions du systeme nerveux central

Publications (1)

Publication Number Publication Date
DE60332481D1 true DE60332481D1 (de) 2010-06-17

Family

ID=32507765

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60332481T Expired - Lifetime DE60332481D1 (de) 2002-12-06 2003-12-05 Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems

Country Status (10)

Country Link
US (1) US7408028B2 (fr)
EP (1) EP1567545B1 (fr)
JP (1) JP2006526382A (fr)
KR (1) KR20050092366A (fr)
CN (1) CN1745094A (fr)
AT (1) ATE466870T1 (fr)
AU (1) AU2003288434B2 (fr)
CA (1) CA2508847A1 (fr)
DE (1) DE60332481D1 (fr)
WO (1) WO2004052922A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG157418A1 (en) * 2004-12-01 2009-12-29 Univ Singapore Nogo a protein fragments as neuronal network- interacting peptides
DE102004062420A1 (de) * 2004-12-20 2006-07-06 Rheinische Friedrich-Wilhelms-Universität Bonn Verfahren zur Isolierung neuraler Zellen mit Tenascin-R-Verbindungen
EP2168979A1 (fr) * 2008-09-23 2010-03-31 Rheinische Friedrich-Wilhelms-Universität Bonn Procédé d'isolation de cellules neurales dotées de liaisons tenascine-R
EP2467491A4 (fr) * 2009-08-21 2014-04-02 Sinai School Medicine Procédés d'utilisation de protéines de fusion de cd44 pour traiter le cancer
CN103122349B (zh) * 2011-10-21 2014-10-15 中国人民解放军第二军医大学 抑制MAG基因表达的siRNA及重组载体
CN103387603B (zh) * 2012-05-08 2015-07-15 复旦大学 一种rtn4b相关多肽及其制备与应用
TWI565712B (zh) 2014-10-20 2017-01-11 福又達生物科技股份有限公司 增進神經元生長的胜肽及其應用
CN107312071B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗方法
US20250353901A1 (en) * 2019-08-08 2025-11-20 On. Target Molecules Biotech Inc. Fusion proteins against sialosylated glycosphingolipids and sialated glycoproteins and uses thereof
WO2021231405A1 (fr) * 2020-05-12 2021-11-18 Board Of Regents, The University Of Texas System Procédés de traitement du glioblastome
CN113249420B (zh) * 2021-05-12 2022-08-26 四川原石科技有限公司 一种提高大鲵肽生物活性的方法、大鲵肽糖基化产物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735984B1 (fr) * 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
MXPA02004283A (es) * 1999-10-29 2002-10-17 Chiron Spa Peptidos antigenicos neisseriales.
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
BR0107613A (pt) * 2000-01-12 2002-11-19 Univ Yale Bloqueio do crescimento de axÈnios mediado por receptor nogo
GB0001825D0 (en) * 2000-01-26 2000-03-22 Regen Therapeutics Plc Peptides
AU2001236589A1 (en) * 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
AU2001233913A1 (en) * 2000-02-25 2001-09-03 Oxford Glycosciences (Uk) Ltd. Bcmp 84, a protein associated to breast cancer
WO2001076532A2 (fr) * 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions et procedes permettant de diagnostiquer et de traiter des etats pathologiques, des troubles ou des maladies faisant intervenir la mort des cellules
WO2003096979A2 (fr) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Pharmacotherapie destinee a une maladie coeliaque
EP1567186A2 (fr) * 2002-12-06 2005-08-31 Singapore General Hospital Pte. Ltd. Nogo, caspr, f3 et nb-3 pour le traitement de blessures et de maladies du systeme nerveux central

Also Published As

Publication number Publication date
US20060205668A1 (en) 2006-09-14
CN1745094A (zh) 2006-03-08
WO2004052922A3 (fr) 2004-10-28
ATE466870T1 (de) 2010-05-15
US7408028B2 (en) 2008-08-05
KR20050092366A (ko) 2005-09-21
EP1567545B1 (fr) 2010-05-05
AU2003288434A1 (en) 2004-06-30
AU2003288434B2 (en) 2011-03-17
EP1567545A2 (fr) 2005-08-31
WO2004052922A2 (fr) 2004-06-24
CA2508847A1 (fr) 2004-06-24
JP2006526382A (ja) 2006-11-24

Similar Documents

Publication Publication Date Title
DE60032486D1 (de) Prion protein peptide und deren verwendung
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE224713T1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
ATE530560T1 (de) Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
NO20061736L (no) Krystallform av epotilon B
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
DE69738868D1 (de) Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
ATE362928T1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
WO2002069900A3 (fr) Procede de traitement de troubles proliferatifs d'origine genetique par des inhibiteurs de hsp90
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
DK1294390T3 (da) Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
DE60332481D1 (de) Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
BR0107691A (pt) Sapogeninas substituìdas e seu uso
DE60223547D1 (de) Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
DK2172208T3 (da) Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: JIANGSU NOVAVAC BIO-TEC CO., LTD., SU ZHOU, CN

8364 No opposition during term of opposition